Vanderbilt University Medical Center, the Translational Genomics Research Institute (TGen), an affiliate of City of Hope and the Norton Thoracic Institute at St. Joseph’s Hospital and Medical Center in Arizona, have received a $3.5 million federal grant to study the cause of idiopathic pulmonary fibrosis (IPF) the nation’s most common and severe form of fibrotic lung disease.

Two early-career physician-scientists at Vanderbilt University Medical Center are among 18 recipients of 2018 Clinical Scientist Development Awards announced July 31 by the Doris Duke Charitable Foundation.

Investigators in the Division of Allergy, Pulmonary and Critical Care have launched a pilot study to see if patients with idiopathic pulmonary fibrosis (IPF) can tolerate the addition of a commonly used antiviral drug to standard IPF treatments. The research team believes the drug may ultimately help slow progression of the chronic and progressive disease or reverse its course.

Two Vanderbilt University Medical Center investigators recently received awards from the ATS Foundation and its partners to support their lung disease-related research efforts.